Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Advances in Thoracic Oncology Multidisciplinary Care
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Advances in Thoracic Oncology Multidisciplinary Care

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pulmonology".

Deadline for manuscript submissions: closed (20 September 2024) | Viewed by 3361

Special Issue Editor

Dr. Nestor Villamizar

E-Mail Website
Guest Editor
Division of Cardiothoracic Surgery, The DeWitt Daughtry Department of Surgery, University of Miami, Miami, FL, USA
Interests: thoracic surgery; foregut surgery; pleural mesothelioma; lung cancer; esophageal and mediastinal resection; minimally invasive robotic surgery; thoracic outlet syndrome
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer care is complex. A multidisciplinary approach results in a more efficient and effective patient-centered care.  Advances in systemic therapy (immunotherapy and target therapy) for lung cancer have improved survival in advanced stages. Recent clinical trials are also demonstrating improved survival in patients with locoregional advanced lung cancer with the combination of chemotherapy, immunotherapy, and surgery. In addition, robotic technology is increasingly being used in the diagnosis and treatment of lung cancer. This Special Issue aims to add to the body of literature reporting the results of current multimodality therapy for locoregional advanced lung cancer in combination with robotic technology. The scope of this Special Issue would include the evaluation of safety and accuracy of robotic navigational bronchoscopy, cost-effectiveness of 3D software to plan complex robotic operations including complex segmentectomy and Pancoast tumors, experience with adoption of virtual platforms for multidisciplinary clinics, safety and oncologic outcomes associated with induction chemo-immunotherapy, and target therapy followed by robotic anatomic resections.

Dr. Nestor Villamizar
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thoracic oncology
  • lung cancer
  • cancer care
  • immunotherapy and target therapy
  • robotic technology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 2958 KiB  
Article
Preventive Aortic Stent Graft Implantation Prior to Thoracic Surgery: Early and Midterm Results
by Olivia Lauk, Bianca Battilana, Didier Schneiter, Isabelle Schmitt-Opitz, Alexander Zimmermann and Benedikt Reutersberg
J. Clin. Med. 2024, 13(19), 5694; https://doi.org/10.3390/jcm13195694 - 25 Sep 2024
Viewed by 1521
Abstract
Background: There is a paucity of data concerning the feasibility and value of thoracic aortic stent graft implantation (TEVAR) applications for removing tumors infiltrating the aortic wall. This analysis aimed to demonstrate the feasibility of TEVAR and monitor the perioperative risks of [...] Read more.
Background: There is a paucity of data concerning the feasibility and value of thoracic aortic stent graft implantation (TEVAR) applications for removing tumors infiltrating the aortic wall. This analysis aimed to demonstrate the feasibility of TEVAR and monitor the perioperative risks of morbidity and mortality. Additionally, a literature review was performed. Methods: A retrospective data analysis was performed on patients who received TEVAR prior to thoracic malignancy resection between January 2010 and April 2024. The primary endpoint was technical success. Results: A total of 15 patients (median age: 67 years; range: 23–75; 66.7% female) received TEVAR prior to thoracic surgery of different tumor entities. In 80% of cases (n = 12), the proximal landing zone was in aortic zone 3. In three cases, the supra-aortic debranching of LSA and/or LCCA via bypass implantation or in situ laser fenestration was necessary. No postoperative endograft-related complications were observed. In eight patients, aortic wall infiltration was confirmed intraoperatively. In total, R0 resection was achieved in seven patients (46.7%). The 30-day mortality rate was 6.7% (n = 1). Technical success was achieved in all patients (100%), while procedural success was achieved in 80% due to incomplete tumor resection in three patients. Conclusions: To the best of our knowledge, this is the largest analysis to date that confirms the results of previous smaller studies. Aortic stent grafting prior to thoracic tumor resection allows for extensive resection while maintaining low morbidity and a low 30-day mortality risk. Full article
(This article belongs to the Special Issue Advances in Thoracic Oncology Multidisciplinary Care)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 297 KiB  
Review
Integrative Approaches in Non-Small Cell Lung Cancer Management: The Role of Radiotherapy
by Maxime A. Visa, Mohamed E. Abazeed and Diego Avella Patino
J. Clin. Med. 2024, 13(15), 4296; https://doi.org/10.3390/jcm13154296 - 23 Jul 2024
Cited by 1 | Viewed by 1173
Abstract
Treatment guidelines for non-small cell lung cancer (NSCLC) vary by several factors including pathological stage, patient candidacy, and goal of treatment. With many therapeutics and even more combinations available in the NSCLC clinician’s toolkit, a multitude of questions remain unanswered vis-a-vis treatment optimization. [...] Read more.
Treatment guidelines for non-small cell lung cancer (NSCLC) vary by several factors including pathological stage, patient candidacy, and goal of treatment. With many therapeutics and even more combinations available in the NSCLC clinician’s toolkit, a multitude of questions remain unanswered vis-a-vis treatment optimization. While some studies have begun exploring the interplay among the many pillars of NSCLC treatment—surgical resection, radiotherapy, chemotherapy, and immunotherapy—the vast number of combinations and permutations of different therapy modalities in addition to the modulation of each constituent therapy leaves much to be desired in a field that is otherwise rapidly evolving. Given NSCLC’s high incidence and lethality, the experimentation of synergistic benefits that combinatorial treatment may confer presents a ripe target for advancement and increased understanding without the cost and burden of novel drug development. This review introduces, synthesizes, and compares prominent NSCLC therapies, placing emphasis on the interplay among types of therapies and the synergistic benefits some combinatorial therapies have demonstrated over the past several years. Full article
(This article belongs to the Special Issue Advances in Thoracic Oncology Multidisciplinary Care)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop